Thyrocare to sell Nueclear Healthcare stake to Trovera for Rs 141.4 cr

Core Business DivestedStrategic Transactions View source PDF Explain this filing

THYROCARE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.2%Reaction day

₹555.00

prior close

₹570.15

announcement price

In-mkt

timing

Nifty Microcap 250market-0.1%+3.3% vs market

Healthcare Service Provider peers, median of 26sector+0.5%+2.7% vs sector

On the reaction day the stock moved 3.3 pts more than Nifty Microcap 250 and 2.7 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.4

10m

+0.6

15m

+0.3

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.2-0.1+3.3+0.5+2.7

Next day

+4.0+0.3+3.7+0.7+3.4

+3.2+1.6+1.6+0.6+2.6

+2.4+0.1+2.4-0.2+2.7

+1.8+0.3+1.5-0.7+2.5

-1.0-1.2+0.3+0.0-1.0

-3.6-0.5-3.1-2.0-1.6

15d

-10.1-2.2-7.9-4.3-5.8

-18.0-6.6-11.4-7.4-10.6

—————

UpDownMarket · Nifty Microcap 250Sector · Healthcare Service Provider peers, median of 26Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Thyrocare board approved selling its entire 100 percent stake in wholly owned subsidiary Nueclear Healthcare (NHL) to Trovera Healthcare for about Rs 141.40 crore. NHL runs the radiology and diagnostic imaging business. Consideration includes Rs 81.90 crore cash and Rs 59.50 crore in Trovera CCPS. NHL contributed 5.38 percent of FY26 consolidated turnover (Rs 44.62 cr) and 14.27 percent of net worth. Company will also buy back its Gurugram and Hyderabad operating properties from NHL for Rs 20.59 crore. Deal subject to shareholder approval, expected by November 30, 2026.

Likely market impact

Exits radiology to sharpen focus on core pathology business; brings in about Rs 82 crore cash but removes a material subsidiary contributing 5 percent of revenue.